Issues

CXCL13-producing follicular helper CD4⁺ T cells and IgG specific to Escherichia coli are biomarkers of clinical benefit of neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer.

Intratumor myeloid inflammation independently predicts metastatic recurrence after nephrectomy in clear-cell renal cell carcinoma (ccRCC) and can be therapeutically targeted in a novel metastatic ccRCC mouse model.

Single-cell profiling of pancreatic ductal adenocarcinoma tumor-infiltrating lymphocytes provides a cell-state trajectory and indicates the GZMK⁺ state as an intermediate between either a GZMB⁺ cytotoxic state or a CXCL13⁺ dysfunctional state.

Multiregional immunogenomic analyses of intrahepatic cholangiocarcinoma (iCCA) demonstrate the cross-talk between tumor evolution and immune composition, providing novel insight into cancer immunoediting and personalized immunotherapy.

Chromosomal alteration of BCL-2 leads to poorer outcomes in patients with lymphoma after anti-CD19 CART therapy, but combination of anti-CD19 CART cells overexpressing a BCL-2 mutant with venetoclax leads to synergistic antitumor effects.

Single-cell transcriptomic profiling of the bone marrow of a TET2-induced animal model of clonal hematopoiesis identifies inflammation as a putative driver of leukemic transformation.

The mitochondrial transaminase GOT2 binds directly to fatty acid ligands that regulate the nuclear receptor PPARδ, and this functional interaction critically regulates the immune microenvironment of pancreatic cancer to promote tumor progression.

Loss-of-function alterations in LZTR1, a Cullin-3 RING E3 ubiquitin ligase adapter, and impaired ubiquitin-mediated degradation of RAS proteins via mutations in RIT1 drive clonal hematopoietic transformation.

Schwann cells undergo c-Jun–mediated reprogramming in pancreatic cancer, analogous to their trans-differentiation following trauma, and collectively organize into dynamic tracks that promote cancer cell invasion.